No­var­tis' big PD-1 bet turns sour; $350M res­ur­rec­tion sto­ry; Con­tra­cep­tive for men heads to clin­ic; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The Drug In­for­ma­tion As­so­ci­a­tion’s an­nu­al meet­ing may not have been on every­one’s radar, but the con­ver­sa­tions there could be just as rel­e­vant for the in­dus­try as a whole. And if you missed End­points se­nior ed­i­tor Zach Bren­nan’s se­ries of fire­side chats and pan­els look­ing at the FDA’s next five years, we now have the full videos and tran­scripts avail­able. Check them out be­low.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.